Opaleye management director buys $29,682 of Grace Therapeutics stock

Opaleye Management Inc., a 10% owner and director of Grace Therapeutics, Inc. (NASDAQ:GRCE), recently purchased additional shares of the company’s common stock. The transactions, which occurred between October 8 and October 12, 2026, totaled 14,632 shares for an aggregate value of $29,682.

The shares were acquired at prices ranging from $2.0175 to $2.0446 per share. One of the transactions, involving 5,340 shares purchased on October 9, 2026, was executed at a weighted average price of $2.0446, with individual share prices ranging from $2.03 to $2.05. The insider buying comes as Grace Therapeutics trades at $1.99, down 48% over the past six months, though InvestingPro analysis suggests the stock is undervalued at current levels.

Following these purchases, Opaleye Management Inc. beneficially owns 2,873,289 shares of Grace Therapeutics common stock indirectly through Opaleye, L.P. Opaleye Management Inc. serves as the investment manager for Opaleye, L.P., and disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest. Analysts maintain a bullish outlook with price targets ranging from $3.90 to $7.83, while InvestingPro offers 6 additional exclusive tips about GRCE’s financial health and growth prospects.